Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.77 |
| ▸ | HTR1D | P28221 | 5/20 | 0.77 |
| ▸ | HTR1A | P08908 | 3/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | HTR6 | P50406 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097373 | 1.00 | HTR1B (0.77) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8789502 | 0.91 | HTR1B (0.76) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8789497 | 0.91 | HTR1B (0.76) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8984140 | 0.89 | HTR1B (0.74) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL7103416 | 0.87 | HTR1B (1.00) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL7103413 | 0.87 | HTR1B (1.00) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL29391208 | 0.87 | HTR1B (1.00) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8790004 | 0.86 | HTR1B (0.80) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8790009 | 0.86 | HTR1B (0.80) | HTR1BHTR1DHTR1ACHRM2ADRA2A | |
| SCHEMBL8789654 | 0.86 | HTR1B (0.68) | HTR1BHTR1DHTR1ACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804433-B1 | INDOLE DERIVATIVE FOR THE TREATMENT OF MIGRAINE | PFIZER LTD (GB) | 2002-09-18 | — | — | EP | claimed |
| US-5945118-A | Indole derivative for the treatment of migraine | PFIZER INC (US) | 1999-08-31 | — | — | US | claimed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | claimed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | claimed |
| US-20030055098-A1 | Method of treatment | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6455567-B1 | TREATING DERMATOLOGICAL DISORDERS BY ADMINISTERING A 3-(PYRROLIDIN-2-YLMETHYL)-5-(AMINOSULFONYLMETHYL)INDOLE | PFIZER INC. | 2002-09-24 | — | — | US | disclosed |
| EP-0804433-B1 | INDOLE DERIVATIVE FOR THE TREATMENT OF MIGRAINE | PFIZER LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-0804433-B1 | INDOLE DERIVATIVE FOR THE TREATMENT OF MIGRAINE | PFIZER LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-0785781-B1 | USE OF INDOLE DERIVATIVES FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS PERIPHERAL NEUROPATHIED, ARTHRITIS, ALLERGIC OR CHRONIC OBSTRUCTIVE AIRWAYS DISEASE, GLAUCOMA AND OCULAR INFLAMMATION | PFIZER LTD (GB) | 2001-12-19 | — | — | EP | disclosed |
| US-5945118-A | Indole derivative for the treatment of migraine | PFIZER INC (US) | 1999-08-31 | — | — | US | disclosed |
| US-5945118-A | Indole derivative for the treatment of migraine | PFIZER INC (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0804433-A1 | INDOLE DERIVATIVE FOR THE TREATMENT OF MIGRAINE | Pfizer Limited (GB) | 1997-11-05 | — | — | EP | disclosed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996011923-A1 | INDOLE DERIVATIVE FOR THE TREATMENT OF MIGRAINE | PFIZER LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055098-A1 | Method of treatment | HRH2, CNR2, HRH1 | HTR1B 155/4885HTR1D 198/4885HTR1A 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.